

DAFTAR PUSTAKA

- Agusni I, Imunologi Penyakit kusta. 2000. Dalam : Sudigdo, Sutedja E, Agusni YH, Sugiri U. Editor. Buku Makalah Lengkap Kursus Imuno-dermatologi I Dokter Spesialis Kulit dan Kelamin. Bandung; Kelompok Studi Dermatologi, 231-244.
- Agusni I, Menaldi SL, 2003. Beberapa prosedur diagnostik baru pada penyakit kusta . Dalam : Daili ES, Menaldi SL, Ismiarto SP, Nilasari H ,editor. Kusta, Kelompok studi morbus hansen Indonesia, Makasar, : 59 – 65
- Alter A, Leseleuc L, Thuc N.V. et al , 2010. Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility, *Hum Genet* 127 (3) : 337 -348.
- Balagon VF, Gelber RH, Abalos RV, 2010. Reactions following completion of 1 and 2 year multidrug therapyn (MDT), *Am J Trop Med Hygiene* 83(3) : 637-44
- Barreto JG, Guimaraes LS, Leao MRn et al, 2011, Anti-PGL-1 seroepidemiology in leprosy cases : household contact amd school children from hyperendemic municipality of the Brazilian Amazon, *Lepr Rev* 82 : 385 - 390
- Belgaumkar VA, Gokhale NR, Mahajan PM, et al., 2007. Circulating cytokine profiles in leprosy patients. *Lepr Rev* 78 : 223–230.
- Berrington WR, Macdonald M, Khadge S, et al., 2010. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. *J Infect Dis* 201 (9) : 1422–1435.
- Chouses GP, Margionis AN, 2002. Adrenocosticosteroid dan Antagonis Adrenokortikal , In : Syabana D, Isbandiati E, Basori A, Soejak M, Uno I, Rahmadhani RB, Zakaria S. Editors. *Katzung BG. Farmakologi dasar dan klinik*, 8th edition, Jakarta, Salemba : 576 - 602,
- Citrashanty I, Suyoso S, Rahmadewi, 2013, Profil serum TNF- α dan Kortisol pada berbagai derajat keparahan ENL yang diterapi Kortikosteroid di RSUD Dr. Soetomo Surabaya, Karya Akhir PPDS Kulit dan Kelamin, FK Unair.
- Cooper MS, Stewart PM, 2003. Corticosteroid insufficienmcy in acutely ill patients. *New England Journal of Med* 348 : 727 – 734.
- Departemen Kesehatan RI, 2007. *Buku Pedoman Nasional Pengendalian Penyakit Kusta*. Cetakan XIX. Jakarta.

- Fava V, Orlova M, Cobat A, Alcais A, et al , 2012. Genetic of Leprosy reaction : an overview, *Mem Inst Oswaldo Cruz*, 107 (1) : 1 -7.
- Gorelik L, Constant S, and Flavel RA, 2001, Laclnism of Transforming Growth Factor b-induced inhibiton of T Helper type 1 Disorientation, *J Exp Med* 195 ; 11 : 1499 - 1505
- Goulart IMB, Figueiredo F, Coimbra T, Foss NT, 1996. Detection of Transforming Growth Factor-B1 in Dermal Lesions of Different Clinical Forms of Leprosy. *American J of Pathology* 148 ; 3 : 911 – 917.
- Goulart MB, Mineo JR adn Foss MT, 2000, Production of transforming growth factor-beta 1 (TGF-B) by blood monocytes from patient with different clinical forms of leprosy, *Clin Exp Immunol* 122 : 330 - 334
- Hamzah M.S., 2001. Pola Penyakit Kusta di RSUD Dr. H. Abdul Moeloek Lampung, MDVI, Volume 28, Supplement II, 200S-204S.
- Harboe M. 1994. Overview of host parasite relations. In Hasting RS (ed) *Leprosy* 2nd ed. Churchill Livingstone Inc. New York : 29 – 45.
- Iyer A, Hatta M, Usman R, et al., 2007. Serum levels of interferon- γ , tumor necrosis faktor- α , soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. *Clinical and Experimental Immunology* 150 : 210 – 216.
- Kahawita IP, Walker SL, Lockwood DNJ, 2008. Towards understanding the pathology of erythema nodosum leprosum. *Royal society of Tropical Medicine and Hygiene* 102 :329 -337.
- HK, Sharma P , 2010. Management of Leprosy Reaction, IAL Textbook of Leprosy, first edition, Ajanta Offset and Packagings Ltd, Ne Delhi, India : 387-399.
- Kaufmann SHE, 1994. Cell mediated immunity. In : Hasting RC, Opromola DVA. Ed *Leprosy* 2nd, Ed. Edinburgh: Churchill Livingstone: 157 – 68.
- Kikuchi I, 2009. Mosuke Murata, the designator of erythema nodosum leprosum. *Lepr rev* 80 (1) : 92 – 95.
- Kiszewski CA, Becerril E, Baquera J, Aguilar LD, Pando H, 2003. Expression of transforming growth factor-B isoforms and their receptors in lepromatous and tuberculoid leprosy. *Scandinavian J of Immunology* 57 : 279 - 285.
- Kumar B , Dogra S, Kaur I, 2004. Epidemiological Characteristics of Leprosy Reactions : 15 Years Experience from North India. *International j of Leprosy* 72 ; 2 : 125-133.

- Listiawan M.Y., 2011, Perbandingan ekspresi TLR2/1, NF- κ B p105/50, N- κ B p65 dan TNF- α pada makrofag penderita eritema nodosum leprosum dengan kusta multibasiler sebagai tanda aktifitas kekebalan alamiah, Disertasi, Program Studi S3 Ilmu Kedokteran, Program Pascasarjana, Universitas Airlangga, Surabaya.
- Leal AM, Magalhaes PK, Souza CS, Foss NT. Adrenocortical hormones and interleukin patterns in leprosy, *Eur J Clin Microbiol. Parasite Immunology* 2003 ; 25 : 457- 61.
- Lockwood DNJ, Nicholis PG, Smith WCS , et al , 2012. Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the INFIR Cohort of Indian patients with multibacillary leprosy. *Plos Neglected Tropical Disease* 6 (6) : e-1702.
- Madan NH, Agarwal K, Chander R, 2011. Serum cytokine profil in leprosy and its correlation with clinic-histopathological profile. *Lepr Rev* 82:371 –82.
- Manandhar R, Master LJW, Roche PW, 1999. Risk factor for Erythema Nodosum Leprosum , *Int Journal of Leprosy* 67,3, Sept : 270 – 8.
- Martiniuk F, Giovinazzo J, Tan AU, 2012. The Emergence of TH17 cytokines during type II reactions (ENL) is teaching about T-cell plasticity. *J Drugs Dermatol* 11 (5) : 626 – 630.
- Moraes MO, Sarno EN, Almeida AS, et al , 1999. Cytokine mRNA expression in leprosy: a possible role for interferon-gamm and interleukin-12 in reactions (RR and ENL). *Scand j Immunol* 50 ; 5 : 541-549.
- Motta A.C.F, Pereira K.J, Tarquinio D.C., et al, 2012, Leprosy reactions : coinfections as a possible risk factor. *Clinics* 67 (10) : 1145 – 1148.
- Moura RS, Calado KL, Olivveira MLW and Skula SB, 2008, Leprosy serologi using PGL-I : a systemic review, *Rev Soc Bras Med Trop* 41: 11 - 18
- Murphy K, Travers P, Walpart M, Janeway's Immunobiology. Seventh edition. 2008. Garland Sciende. New York. 323 -77.
- Naafs B. 2000. Current views on Reaction in Leprosy. *Indian j Leprosy*. Vol 72 (1) : 97 – 122.
- Nakamura K, Kitani A and Strober W, 2001, Cell Contact-dependent immunosuprespression by CD4 CD25 regulatory T cells is mediated by cell curfacebond Transforming growth factor B, *journal of Experimental Medicine* 195 ; 4 ; 5 : 629 -644
- Oelker W, 1996. Adrenal Insufficiency. *The New England Journal of Medicine* : 1206 -12

- Pamuji R, 2011. Hubungan adrenalin, Malondialdehyde, antibody IgM anti PGL-1 dan Antibodi anti PGL-1 dengan kejadian reaksi Erythema Nodosum Leprosum, Thesis, Pascasarjana Universitas Airlangga, Surabaya.
- Parslow TB, 1997. The immune response. In : Stites DP, Terr AL, Parslow TG eds. Medical Immunology, 9 th ed, London, Prentice Hall International Inc. ch 4 : 63-73.
- Pocaterra L, Jain S, Reddy R, 2006. Clinical course of erythema nodosum leprosum : an 11 yeear cohort study in Hyderabad India. Am J Trop Med Hyg 74 (5) : 868 -879.
- Prasad PVS, Kaviarasan PK, 2010. Leprosy therapy, past and present : Can we hope to eliminate it. Indian J Dermatol 55 ; 4 : 316-324.
- Quaresma Jas, Almeida FAC, Aarrao TLS et al, 2012, Transforming growth factor B and apoptosis in leprosy skin lesions : possible relationship with the control of tissue immune response in mycobacterium leprae infection, Microbes Infection 14 : 696 – 701
- Rhen T, Cidlowski JA. Anti inflammatory action of glucocorticoid – new mechanisms for old drug . The New England J of Med 2005 ; 353 : 1711
- Ridley DS , Jopling WH., 1966 . Classification of leprosy according to immunity. A five-group system. International Journal of Leprosy and Other Mycobacterial Diseases 34 (3) : 255–273.
- Rifai M, 2009, Signal Transduksi dan Sistem Pertahanan tubuh , Buku Ajar Fisiologi MAB4232, FMIPA UNBRAU, Malang, Penerbit Galaxy Science : Hal 1– 23.
- Rodrigues LS, Hacker MA, Illaramendi X, Pinheiro MF, Nery JA et al, 2011. Circulating level of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy, BMC Infectious Disease ; 11 : 1 – 8.
- Rook GAW, Baker W, 1999, Cortisol metabolism, cortisol sensitivity and the pathogenesis of leprosy reaction. Tropical Medicine and International Journal Health 4 (7) : 493 – 498.
- Rojas R E , Demichelis S O, Sarno E N, Eiras A S, 1997. IgM anti-phenolic glycolipid I and IgG anti 10-kDa hat shock protein antibody in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. FEMS Immunology and medical microbiology 19 : 65 -74.
- Sales AM, de Matos HJ, Nery JAC, 2007. Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. Brazilian J of Medical and Biological Reseach 40 : 243 – 248.

- Sampaio E.P., Oliveira R.B., Davies J.W et al, 2000, T cell-monocyte contact enhances Tumor Necrosis Factor-alpha production in response to Mycobacterium leprae. *Journal of Infectious Disease* 182 : 1463 -72.
- Schimmer PB, Palker KL, 2001. Adrenocorticotrophic hormone: Adrenocortical steroids and their synthetic analogues; inhibitor of the synthesis and actions of adrenocortical. In : Hardman JG, Limbird LE, Gilman AG, editors. *Goodman and Gilman's The Pharmacological Basis of Therapeutic*, 10th edition. New York: McGraw-Hill : 1649 – 74.
- Scollard DM, Adams-Gillis TP, Rahenbuih JL, Truman RW, Williams DL, 2006. The Continuing challenges of Leprosy. *Clin Microbiology Rev* 19 : 338 – 381.
- Silva EA, Iyer A, Ura S., Is , et al, 2007. Utility of measuring serum levels of anti PGL-1 antibody, neopterin and c-reactive protein in monitoring leprosy patients during multidrug treatment and reactions. *Trop Med and Int Med* 12 : 1450 – 1458
- Smetts RB, Chen J and Shevach EM, 2005, Transforming Growth factor-B1 enhances the interferon- γ -dependent, Interleukin 12 independent pathway of T helper 1 cell differentiation, *Immunology* 114 : 484 – 492.
- Soenarto K, 2012, Sepuluh besar kelompok penyakit kulit, Palembang, Penerbit Unsri Press : 204.
- Spencer JS, Brennan PJ, 2011, The role of Mycobacterium leprae Phenolic Glycolipid I (PGL-1) in serodiagnosis and in Pathogenesis of Leprosy, *Lev Rev* 82 ; 344 -357
- Spencer JS, Kim HJ, Wheat WH et al, 2011, Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan and recombinant protein to define disease subtype-specific antigenic profile in leprosy, *Clinical and Vaccine Immunology* 18 ; 2 : 260 - 267
- Stevani MMA, Martelli CMT, Morais-Neto OL et al, 2012, Assesment of Anti PGL-1 as a prognostiv marker of leprosy reaction, *International Journal of Leprosy* 66 ; 3 : 356 -360.
- Suryohudoyo P, 2000, Oksidan, Antioksidan dan Radikal bebas. Dalam : Ilmu Kedokteran molekuler , Kapita Selecta , Jakarta , Agung Seto : 31 -46.
- Taylor A, Verhagen J, Blaser K, Akdis CA, 2006, Mechanisms of Immune suppresion by inteluekin-10 and transforming growth factor-B : the role of T reulatory Cells, *Immunology Review Article* 117 : 433 - 442

- Van Veen NHJ, Lockwood DNJ, Van Brakel WH, et al, 2009. Intervention for erythema nodosum leprosum. Cochrane Database of Systematic review Issue 3 : 1 – 53.
- Verhagen CE, Faber WR, Klatser P, et al., 1999. Immunohistological analysis of in situ expression of mycobacterial antigens in skin lesions of leprosy patients across the histopathological spectrum. *American J of Pathology* 154 (6) : 1793 – 1804.
- Vieira L.M.M, Sampaio E.P, Nery J.A.C et al, 1996. Immunological status of Erythema nodosum leprosum patients : its relationship to bacterial load and levels of circulating IL-2R. *Rev Inst Med trop Sao Paulo* 38(2):103-11
- Walker SL, Lockwood DN. 2006. The clinical and immunological features of leprosy. *British Medical Bulletin* ;77 :108 -121.
- Walker SL, Waters MF, Lockwood DN. 2007. The role of thalidomide in the management of erythema nodosum leprosum . *Lepr Rev* ;78:197-215
- Walsh DS, Lane J, Abalos RM, Myint KSA, 2004. TUNEL and limited olf K, Goldsmith LA, Katz SI, Gilchrist BA, Paller, Leffell DJ. Editors. *Fitzpatrick's Dermatology in General Medicine*, 7th ed. New York. Mc GrawHill : 2147 -53.
- Werth VW. Systemic Glucocorticoid. in Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ. Editor. *Fitzpatrick's Dermatology in General Medicine*. 7th ed. New York : McGrawHill; 2008. p.2147-53
- Widmer IE, Puder JJ, Konig C, Parger H, Zerkowski HR, Girard J et al. Cortisol response in relation to severity of stress and illness. *The Journal of Clinical Endocrinology and Metabolism* 2005 ;90 (8): 4579-96..
- WHO, 2013. *Weekly Epidemiological record*.35: 365 -380.
- WHO, 2000. *Guide to eliminate leprosy as public health problem*, Geneva:1-5
- Yamamura M.,1992,Defining protective responses to pathogens: cytokine profiles in leprosy lesions. *Science*255:12.
- Zenha EMR, Ferreira MAN and Foss NT, 2009, Use of anti-PGL-1 antibodies to monitor therapy regimens in leprosy patients, *Braz J Med Biol Res* 42 ; 10 : 868 - 97